Blood, ISSN 0006-4971, 05/2006, Volume 107, Issue 9, pp. 3753 - 3760
An ex vivo photochemical treatment (PCT) process was developed to inactivate pathogens in fresh frozen plasma (PCT-FFP). A prospective, controlled,...
PATHOGEN INACTIVATION | VIRUS-INFECTION | SAFETY | PLATELET | COMPONENTS | S-59 | RANDOMIZED-TRIAL | SOLVENT/DETERGENT | THROMBOTIC THROMBOCYTOPENIC PURPURA | HEMATOLOGY | TRANSPLANTATION | Liver Diseases - blood | Plasma | Liver Transplantation | Prospective Studies | Double-Blind Method | Humans | Middle Aged | Prothrombin Time | Factor VII - metabolism | Liver Diseases - therapy | Male | Blood Coagulation Disorders - therapy | Blood Transfusion | Hemostasis | Partial Thromboplastin Time | Blood Coagulation Disorders - blood | Female | Aged | Photopheresis | Safety
PATHOGEN INACTIVATION | VIRUS-INFECTION | SAFETY | PLATELET | COMPONENTS | S-59 | RANDOMIZED-TRIAL | SOLVENT/DETERGENT | THROMBOTIC THROMBOCYTOPENIC PURPURA | HEMATOLOGY | TRANSPLANTATION | Liver Diseases - blood | Plasma | Liver Transplantation | Prospective Studies | Double-Blind Method | Humans | Middle Aged | Prothrombin Time | Factor VII - metabolism | Liver Diseases - therapy | Male | Blood Coagulation Disorders - therapy | Blood Transfusion | Hemostasis | Partial Thromboplastin Time | Blood Coagulation Disorders - blood | Female | Aged | Photopheresis | Safety
Journal Article
Hepatology (Baltimore, Md.), ISSN 0270-9139, 10/2012, Volume 56, Issue 4, pp. 1311 - 1318
The PIVENS [Pioglitazone versus Vitamin E versus Placebo for the Treatment of Non-diabetic Patients with Nonalcoholic Steatohepatitis (NASH)] trial...
adipose tissue | pioglitazone | Nonalcoholic steatohepatitis | insulin resistance | vitamin E
adipose tissue | pioglitazone | Nonalcoholic steatohepatitis | insulin resistance | vitamin E
Journal Article
Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 2014, Volume 12, Issue 7, pp. 1170 - 1178
Background & Aims Iron deficiency is often observed in obese individuals. The iron regulatory hormone hepcidin is regulated by iron and cytokines interleukin...
Gastroenterology and Hepatology | Ferroportin | NAFLD | Inflammation | Nutrition | NASH CRN | BMI | UNITED-STATES | POPULATION | TRANSCRIPTION | HYPOFERREMIA | IN-VIVO | ANEMIA | GASTROENTEROLOGY & HEPATOLOGY | EXPRESSION | ADIPOSE-TISSUE | Body Mass Index | Obesity - complications | Humans | Middle Aged | Risk Factors | Hepcidins - blood | Male | Interleukin-1beta - blood | Non-alcoholic Fatty Liver Disease - complications | Young Adult | Interleukin-6 - blood | Iron - deficiency | Sex Factors | Aged, 80 and over | Adult | Alaska | Female | Aged | Continental Population Groups | Serum - chemistry | Obesity | Care and treatment | Fatty liver | Risk factors
Gastroenterology and Hepatology | Ferroportin | NAFLD | Inflammation | Nutrition | NASH CRN | BMI | UNITED-STATES | POPULATION | TRANSCRIPTION | HYPOFERREMIA | IN-VIVO | ANEMIA | GASTROENTEROLOGY & HEPATOLOGY | EXPRESSION | ADIPOSE-TISSUE | Body Mass Index | Obesity - complications | Humans | Middle Aged | Risk Factors | Hepcidins - blood | Male | Interleukin-1beta - blood | Non-alcoholic Fatty Liver Disease - complications | Young Adult | Interleukin-6 - blood | Iron - deficiency | Sex Factors | Aged, 80 and over | Adult | Alaska | Female | Aged | Continental Population Groups | Serum - chemistry | Obesity | Care and treatment | Fatty liver | Risk factors
Journal Article
Hepatology, ISSN 0270-9139, 01/2004, Volume 39, Issue 1, pp. 230 - 238
The current policy for determining priority for organ allocation is based on the model for end stage liver disease (MELD). We hypothesize that severity of...
MODELS | REJECTION | IMMUNOSUPPRESSION | DISEASE | RISK | RECURRENCE | INFECTION | TRANSPLANT RECIPIENTS | GASTROENTEROLOGY & HEPATOLOGY | HEPATITIS-C | PROGRESSION | Predictive Value of Tests | Reproducibility of Results | Prognosis | Humans | Liver Transplantation - mortality | Preoperative Care | Resource Allocation | Survival Analysis | Liver Diseases - mortality | Adult | Liver Diseases - surgery | Reoperation - mortality | Cohort Studies
MODELS | REJECTION | IMMUNOSUPPRESSION | DISEASE | RISK | RECURRENCE | INFECTION | TRANSPLANT RECIPIENTS | GASTROENTEROLOGY & HEPATOLOGY | HEPATITIS-C | PROGRESSION | Predictive Value of Tests | Reproducibility of Results | Prognosis | Humans | Liver Transplantation - mortality | Preoperative Care | Resource Allocation | Survival Analysis | Liver Diseases - mortality | Adult | Liver Diseases - surgery | Reoperation - mortality | Cohort Studies
Journal Article
Gastroenterology, ISSN 0016-5085, 2005, Volume 129, Issue 2, pp. 494 - 503
Previous uncontrolled studies have suggested that patients with hepatic iron overload have a poor outcome after liver transplantation. We examined the effect...
SERUM FERRITIN | VARIABILITY | B VIRUS-INFECTION | LONG-TERM SURVIVAL | CIRRHOSIS | HEREDITARY HEMOCHROMATOSIS | RECIPIENTS | GASTROENTEROLOGY & HEPATOLOGY | Care and treatment | Transplantation | Hemochromatosis | Patient outcomes | Liver
SERUM FERRITIN | VARIABILITY | B VIRUS-INFECTION | LONG-TERM SURVIVAL | CIRRHOSIS | HEREDITARY HEMOCHROMATOSIS | RECIPIENTS | GASTROENTEROLOGY & HEPATOLOGY | Care and treatment | Transplantation | Hemochromatosis | Patient outcomes | Liver
Journal Article
Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 2005, Volume 3, Issue 1, pp. 75 - 84
HCV-related cirrhosis is a leading risk factor for hepatocellular carcinoma (HCC). Surveillance might detect HCC at a treatable stage. We estimated the...
PROGNOSTIC FACTORS | UNITED-STATES | LIVING-DONOR | LIFE-EXPECTANCY | NATURAL-HISTORY | COMPENSATED CIRRHOSIS | EFFECTIVENESS PERSPECTIVE | RETROSPECTIVE ANALYSIS | MULTIVARIATE-ANALYSIS | GASTROENTEROLOGY & HEPATOLOGY | DONOR LIVER-TRANSPLANTATION | Carcinoma, Hepatocellular - economics | Humans | Middle Aged | Liver Neoplasms - economics | Liver Neoplasms - etiology | Liver Cirrhosis - diagnostic imaging | Hepatitis C - blood | Adult | Hepatitis C - complications | Carcinoma, Hepatocellular - etiology | Hepatitis C - diagnostic imaging | Clinical Laboratory Techniques - economics | alpha-Fetoproteins - metabolism | Quality-Adjusted Life Years | Carcinoma, Hepatocellular - diagnosis | Decision Support Techniques | Carcinoma, Hepatocellular - surgery | Liver Neoplasms - surgery | Liver Cirrhosis - blood | Liver Transplantation - economics | Ultrasonography - economics | Liver Cirrhosis - virology | Liver Neoplasms - diagnosis | Cost-Benefit Analysis | Monte Carlo Method | Care and treatment | Analysis | Transplantation of organs, tissues, etc | Markov processes | Hepatoma | Hepatitis C | Liver cirrhosis | Donation of organs, tissues, etc
PROGNOSTIC FACTORS | UNITED-STATES | LIVING-DONOR | LIFE-EXPECTANCY | NATURAL-HISTORY | COMPENSATED CIRRHOSIS | EFFECTIVENESS PERSPECTIVE | RETROSPECTIVE ANALYSIS | MULTIVARIATE-ANALYSIS | GASTROENTEROLOGY & HEPATOLOGY | DONOR LIVER-TRANSPLANTATION | Carcinoma, Hepatocellular - economics | Humans | Middle Aged | Liver Neoplasms - economics | Liver Neoplasms - etiology | Liver Cirrhosis - diagnostic imaging | Hepatitis C - blood | Adult | Hepatitis C - complications | Carcinoma, Hepatocellular - etiology | Hepatitis C - diagnostic imaging | Clinical Laboratory Techniques - economics | alpha-Fetoproteins - metabolism | Quality-Adjusted Life Years | Carcinoma, Hepatocellular - diagnosis | Decision Support Techniques | Carcinoma, Hepatocellular - surgery | Liver Neoplasms - surgery | Liver Cirrhosis - blood | Liver Transplantation - economics | Ultrasonography - economics | Liver Cirrhosis - virology | Liver Neoplasms - diagnosis | Cost-Benefit Analysis | Monte Carlo Method | Care and treatment | Analysis | Transplantation of organs, tissues, etc | Markov processes | Hepatoma | Hepatitis C | Liver cirrhosis | Donation of organs, tissues, etc
Journal Article
Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 2007, Volume 5, Issue 2, pp. e7 - e7
Journal Article
Journal of Neurotrauma, ISSN 0897-7151, 08/2018, Volume 35, Issue 16, pp. A-1 - A-285
[...]the vast majority of basic science pain research ends at target identification and validation in rodent models of chronic pain without confirmation in...
Abstracts | Neurosciences | Keywords | Traumatic brain injury | Cytokines | Central nervous system | Inflammation | Gene expression | Trauma | Studies | Brain research | Hospitals | Pain | Rodents | Stem cells | DNA methylation | Biomarkers | Spinal cord injuries | Growth factors | Research centers | Proteins
Abstracts | Neurosciences | Keywords | Traumatic brain injury | Cytokines | Central nervous system | Inflammation | Gene expression | Trauma | Studies | Brain research | Hospitals | Pain | Rodents | Stem cells | DNA methylation | Biomarkers | Spinal cord injuries | Growth factors | Research centers | Proteins
Journal Article
Gastroenterology and Hepatology, ISSN 1554-7914, 04/2010, Volume 6, Issue 4, pp. 1 - 9
Cirrhosis of the liver is a rising epidemic in the United States, affecting 2 out of every 1,000 adults. It is responsible for the deaths of more than 27,000...
CMExpress Opportunity
CMExpress Opportunity
Journal Article
The Journal of pharmacology and experimental therapeutics, ISSN 0022-3565, 07/2004, Volume 310, Issue 1, p. 417
Alcoholic liver disease is associated with a state of hepatic fatty acid overload. We examined the effect of ethanol and different types of dietary fat on the...
Tumor Necrosis Factor-alpha - metabolism | Up-Regulation | Fatty Acid-Binding Proteins | Acyl-CoA Oxidase - metabolism | Rats, Wistar | Cyclooxygenase 2 | Male | NF-kappa B - metabolism | Clofibrate - therapeutic use | Isoenzymes - metabolism | Ethanol - adverse effects | Lipid Peroxidation - drug effects | Liver Diseases, Alcoholic - pathology | Transcription Factors - physiology | Fatty Liver - metabolism | Gene Expression Regulation - physiology | Rats | Receptors, Cytoplasmic and Nuclear - physiology | Fatty Liver - drug therapy | Liver Diseases, Alcoholic - metabolism | Gene Expression Regulation - drug effects | Transcription Factors - metabolism | Animals | Carrier Proteins - metabolism | Prostaglandin-Endoperoxide Synthases - metabolism | Receptors, Cytoplasmic and Nuclear - metabolism
Tumor Necrosis Factor-alpha - metabolism | Up-Regulation | Fatty Acid-Binding Proteins | Acyl-CoA Oxidase - metabolism | Rats, Wistar | Cyclooxygenase 2 | Male | NF-kappa B - metabolism | Clofibrate - therapeutic use | Isoenzymes - metabolism | Ethanol - adverse effects | Lipid Peroxidation - drug effects | Liver Diseases, Alcoholic - pathology | Transcription Factors - physiology | Fatty Liver - metabolism | Gene Expression Regulation - physiology | Rats | Receptors, Cytoplasmic and Nuclear - physiology | Fatty Liver - drug therapy | Liver Diseases, Alcoholic - metabolism | Gene Expression Regulation - drug effects | Transcription Factors - metabolism | Animals | Carrier Proteins - metabolism | Prostaglandin-Endoperoxide Synthases - metabolism | Receptors, Cytoplasmic and Nuclear - metabolism
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2010, Volume 362, Issue 25, pp. 2423 - 2425
To the Editor: Bass et al. (March 25 issue) 1 conducted a randomized, double-blind, placebo-controlled trial comparing 6-month rifaximin therapy with placebo...
MEDICINE, GENERAL & INTERNAL | Rifamycins - therapeutic use | Liver Cirrhosis - complications | Humans | Peritonitis - prevention & control | Gastrointestinal Agents - therapeutic use | Peritonitis - complications | Anti-Infective Agents - therapeutic use | Hepatic Encephalopathy - complications | Hepatic Encephalopathy - prevention & control | Conflicts of interest | Hospitalization | Hospitals | Liver cirrhosis | Hepatology
MEDICINE, GENERAL & INTERNAL | Rifamycins - therapeutic use | Liver Cirrhosis - complications | Humans | Peritonitis - prevention & control | Gastrointestinal Agents - therapeutic use | Peritonitis - complications | Anti-Infective Agents - therapeutic use | Hepatic Encephalopathy - complications | Hepatic Encephalopathy - prevention & control | Conflicts of interest | Hospitalization | Hospitals | Liver cirrhosis | Hepatology
Journal Article
Contemporary Clinical Trials, ISSN 1551-7144, 2009, Volume 31, Issue 1, pp. 62 - 70
Abstract Background Nonalcoholic fatty liver disease (NAFLD) in children can lead to steatohepatitis, cirrhosis, and end-stage liver disease. The cause of...
Hematology, Oncology and Palliative Medicine | Cardiovascular | Nonalcoholic steatohepatitis | Vitamin E | Nonalcoholic fatty liver | Metformin | Children | Randomized controlled trial | RRR-α-tocopherol | MEDICINE, RESEARCH & EXPERIMENTAL | VITAMIN-E | PREVALENCE | RRR-alpha-tocopherol | HEPATIC CYTOCHROME-P450 2E1 | NATURAL-HISTORY | NASH | OBESE CHILDREN | INSULIN-RESISTANCE | ADOLESCENTS | PHARMACOLOGY & PHARMACY | STEATOHEPATITIS | ASSOCIATION | Hypoglycemic Agents - therapeutic use | Liver Function Tests | Metformin - therapeutic use | Double-Blind Method | Humans | Male | Alanine Transaminase - blood | Fatty Liver - drug therapy | Patient Selection | Adolescent | Fatty Liver - enzymology | Vitamin E - therapeutic use | Female | Child | Research Design | nonalcoholic steatohepatitis | nonalcoholic fatty liver | children | vitamin E | metformin | randomized controlled trial
Hematology, Oncology and Palliative Medicine | Cardiovascular | Nonalcoholic steatohepatitis | Vitamin E | Nonalcoholic fatty liver | Metformin | Children | Randomized controlled trial | RRR-α-tocopherol | MEDICINE, RESEARCH & EXPERIMENTAL | VITAMIN-E | PREVALENCE | RRR-alpha-tocopherol | HEPATIC CYTOCHROME-P450 2E1 | NATURAL-HISTORY | NASH | OBESE CHILDREN | INSULIN-RESISTANCE | ADOLESCENTS | PHARMACOLOGY & PHARMACY | STEATOHEPATITIS | ASSOCIATION | Hypoglycemic Agents - therapeutic use | Liver Function Tests | Metformin - therapeutic use | Double-Blind Method | Humans | Male | Alanine Transaminase - blood | Fatty Liver - drug therapy | Patient Selection | Adolescent | Fatty Liver - enzymology | Vitamin E - therapeutic use | Female | Child | Research Design | nonalcoholic steatohepatitis | nonalcoholic fatty liver | children | vitamin E | metformin | randomized controlled trial
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/1999, Volume 341, Issue 6, p. 443
Renal failure develops in 30 to 40 percent of patients, even after the infection has been brought under control, and it remains a major cause of death.3 In...
Plasma | Liver diseases | Mortality | Infections | Liver cirrhosis | Drug dosages
Plasma | Liver diseases | Mortality | Infections | Liver cirrhosis | Drug dosages
Journal Article
The American Journal of Cardiology, ISSN 0002-9149, 03/2009, Volume 103, Issue 5, p. 742
Patients with end-stage liver disease (ESLD) are predisposed to bleeding complications due to thrombocytopenia, reduced synthesis of coagulation factors, and...
Blood transfusions | Heart | Liver diseases | Transplants & implants | Coagulation | Intubation
Blood transfusions | Heart | Liver diseases | Transplants & implants | Coagulation | Intubation
Journal Article
Gastroenterology, ISSN 0016-5085, 04/2001, Volume 120, Issue 5, pp. A377 - A377
Journal Article
Hepatology, ISSN 0270-9139, 1995, Volume 21, Issue 3, pp. 709 - 716
Cirrhosis is frequently complicated by ascites that may become resistant to diuretic therapy. Transjugular intrahepatic portosystemic shunts (TIPS) represent a...
Journal Article
97.
Full Text
It could have been something they ate – functional food and the treatment of liver cancer
Journal of Hepatology, ISSN 0168-8278, 2002, Volume 37, Issue 1, pp. 147 - 150
Journal Article
Clinical Transplantation, ISSN 0902-0063, 08/2005, Volume 19, Issue 4, pp. 501 - 506
: Background: Most cases of Budd–Chiari syndrome (BCS) in Western countries are related to underlying hematologic diseases with inherent thrombogenic...
recurrence | Budd–Chiari syndrome | thrombosis | orthotopic liver transplantation | bleeding complications | Recurrence | Budd-Chiari syndrome | Thrombosis | Bleeding complications | Orthotopic liver transplantation | SURVIVAL | SURGERY | PORTOSYSTEMIC SHUNT | SURGICAL-TREATMENT | TRANSPLANTATION | THERAPY | DISEASE | EXPERIENCE | TIPS | Anticoagulants - administration & dosage | Humans | Middle Aged | Graft Survival | Liver Transplantation - mortality | Male | Portal Vein | Budd-Chiari Syndrome - surgery | Hematologic Diseases - etiology | Pulmonary Embolism - etiology | Thrombosis - etiology | Hemorrhage - etiology | Adult | Female | Retrospective Studies | Postoperative Complications
recurrence | Budd–Chiari syndrome | thrombosis | orthotopic liver transplantation | bleeding complications | Recurrence | Budd-Chiari syndrome | Thrombosis | Bleeding complications | Orthotopic liver transplantation | SURVIVAL | SURGERY | PORTOSYSTEMIC SHUNT | SURGICAL-TREATMENT | TRANSPLANTATION | THERAPY | DISEASE | EXPERIENCE | TIPS | Anticoagulants - administration & dosage | Humans | Middle Aged | Graft Survival | Liver Transplantation - mortality | Male | Portal Vein | Budd-Chiari Syndrome - surgery | Hematologic Diseases - etiology | Pulmonary Embolism - etiology | Thrombosis - etiology | Hemorrhage - etiology | Adult | Female | Retrospective Studies | Postoperative Complications
Journal Article